Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TSHA |
---|---|---|
09:32 ET | 12427 | 2.27 |
09:34 ET | 1654 | 2.27 |
09:36 ET | 8470 | 2.29 |
09:38 ET | 972 | 2.29 |
09:39 ET | 1036 | 2.285 |
09:41 ET | 2279 | 2.3 |
09:43 ET | 1501 | 2.295 |
09:45 ET | 3097 | 2.295 |
09:48 ET | 777 | 2.31 |
09:50 ET | 1816 | 2.305 |
09:52 ET | 1025 | 2.305 |
09:54 ET | 1613 | 2.315 |
09:56 ET | 11621 | 2.3452 |
09:57 ET | 2920 | 2.32 |
09:59 ET | 1272 | 2.3 |
10:01 ET | 5246 | 2.32 |
10:03 ET | 1199 | 2.305 |
10:06 ET | 200 | 2.295 |
10:08 ET | 2944 | 2.3 |
10:10 ET | 4602 | 2.28 |
10:12 ET | 5800 | 2.305 |
10:14 ET | 2405 | 2.28 |
10:15 ET | 1769 | 2.27 |
10:17 ET | 3524 | 2.28 |
10:19 ET | 900 | 2.27 |
10:21 ET | 3600 | 2.265 |
10:24 ET | 4391 | 2.26 |
10:26 ET | 6225 | 2.265 |
10:28 ET | 4552 | 2.27 |
10:30 ET | 100 | 2.265 |
10:32 ET | 2530 | 2.25 |
10:33 ET | 1936 | 2.245 |
10:35 ET | 18125 | 2.2699 |
10:37 ET | 1310 | 2.265 |
10:39 ET | 1000 | 2.265 |
10:42 ET | 2594 | 2.275 |
10:44 ET | 400 | 2.27 |
10:46 ET | 700 | 2.27 |
10:48 ET | 400 | 2.275 |
10:50 ET | 3066 | 2.265 |
10:51 ET | 2574 | 2.265 |
10:53 ET | 2000 | 2.265 |
10:55 ET | 1866 | 2.27 |
10:57 ET | 2742 | 2.27 |
11:00 ET | 758 | 2.275 |
11:02 ET | 1058 | 2.275 |
11:04 ET | 520 | 2.275 |
11:06 ET | 930 | 2.275 |
11:08 ET | 1300 | 2.2756 |
11:09 ET | 751 | 2.275 |
11:13 ET | 340 | 2.27 |
11:15 ET | 3200 | 2.265 |
11:18 ET | 1170 | 2.265 |
11:20 ET | 1900 | 2.255 |
11:22 ET | 3258 | 2.25 |
11:24 ET | 300 | 2.255 |
11:26 ET | 1289 | 2.26 |
11:27 ET | 5529 | 2.26 |
11:31 ET | 2071 | 2.27 |
11:33 ET | 200 | 2.275 |
11:36 ET | 200 | 2.28 |
11:38 ET | 300 | 2.275 |
11:40 ET | 3010 | 2.285 |
11:44 ET | 3870 | 2.275 |
11:45 ET | 800 | 2.28 |
11:47 ET | 3234 | 2.275 |
11:49 ET | 100 | 2.275 |
11:51 ET | 100 | 2.28 |
11:54 ET | 100 | 2.275 |
11:56 ET | 3108 | 2.27 |
11:58 ET | 1496 | 2.2601 |
12:00 ET | 1734 | 2.28 |
12:03 ET | 200 | 2.275 |
12:07 ET | 6915 | 2.28 |
12:09 ET | 4981 | 2.275 |
12:12 ET | 1294 | 2.275 |
12:14 ET | 1195 | 2.26 |
12:16 ET | 1400 | 2.265 |
12:20 ET | 789 | 2.26 |
12:21 ET | 2266 | 2.265 |
12:23 ET | 2963 | 2.25 |
12:25 ET | 400 | 2.255 |
12:27 ET | 100 | 2.26 |
12:32 ET | 300 | 2.255 |
12:36 ET | 393 | 2.26 |
12:38 ET | 300 | 2.255 |
12:39 ET | 100 | 2.255 |
12:41 ET | 200 | 2.26 |
12:43 ET | 2794 | 2.255 |
12:45 ET | 5602 | 2.255 |
12:48 ET | 1727 | 2.255 |
12:50 ET | 1651 | 2.25 |
12:52 ET | 3402 | 2.23 |
12:54 ET | 2292 | 2.235 |
12:56 ET | 700 | 2.235 |
12:57 ET | 708 | 2.235 |
12:59 ET | 9795 | 2.22 |
01:01 ET | 300 | 2.23 |
01:03 ET | 1089 | 2.22 |
01:06 ET | 2495 | 2.23 |
01:08 ET | 556 | 2.2333 |
01:10 ET | 512 | 2.235 |
01:12 ET | 700 | 2.24 |
01:14 ET | 400 | 2.24 |
01:15 ET | 4775 | 2.225 |
01:17 ET | 1589 | 2.23 |
01:19 ET | 900 | 2.22 |
01:21 ET | 600 | 2.23 |
01:24 ET | 2951 | 2.225 |
01:26 ET | 1000 | 2.225 |
01:28 ET | 200 | 2.22 |
01:30 ET | 1200 | 2.225 |
01:32 ET | 200 | 2.225 |
01:33 ET | 300 | 2.23 |
01:35 ET | 11391 | 2.21 |
01:37 ET | 3608 | 2.215 |
01:39 ET | 3966 | 2.21 |
01:42 ET | 2093 | 2.215 |
01:44 ET | 2685 | 2.22 |
01:46 ET | 1500 | 2.2268 |
01:48 ET | 1300 | 2.24 |
01:50 ET | 900 | 2.235 |
01:51 ET | 620 | 2.24 |
01:53 ET | 175 | 2.235 |
01:55 ET | 2089 | 2.23 |
02:00 ET | 700 | 2.24 |
02:02 ET | 300 | 2.235 |
02:04 ET | 12692 | 2.265 |
02:06 ET | 16583 | 2.275 |
02:08 ET | 3786 | 2.27 |
02:09 ET | 1300 | 2.265 |
02:11 ET | 1857 | 2.275 |
02:13 ET | 600 | 2.275 |
02:15 ET | 2331 | 2.275 |
02:18 ET | 800 | 2.275 |
02:20 ET | 7367 | 2.285 |
02:22 ET | 5360 | 2.285 |
02:24 ET | 1500 | 2.285 |
02:26 ET | 1126 | 2.285 |
02:27 ET | 12207 | 2.285 |
02:29 ET | 2419 | 2.275 |
02:31 ET | 3343 | 2.27 |
02:33 ET | 2900 | 2.28 |
02:36 ET | 5128 | 2.285 |
02:38 ET | 3100 | 2.285 |
02:40 ET | 3289 | 2.285 |
02:42 ET | 3300 | 2.285 |
02:44 ET | 2200 | 2.285 |
02:45 ET | 1134 | 2.29 |
02:47 ET | 900 | 2.285 |
02:49 ET | 2291 | 2.29 |
02:51 ET | 3443 | 2.295 |
02:54 ET | 3317 | 2.3 |
02:56 ET | 2900 | 2.295 |
02:58 ET | 8900 | 2.3 |
03:00 ET | 6310 | 2.3 |
03:02 ET | 2946 | 2.295 |
03:03 ET | 25636 | 2.295 |
03:05 ET | 42496 | 2.28 |
03:07 ET | 8083 | 2.285 |
03:09 ET | 3850 | 2.285 |
03:12 ET | 6567 | 2.29 |
03:14 ET | 6919 | 2.29 |
03:16 ET | 4700 | 2.285 |
03:18 ET | 2402 | 2.285 |
03:20 ET | 1400 | 2.285 |
03:21 ET | 10751 | 2.295 |
03:23 ET | 2800 | 2.295 |
03:25 ET | 42052 | 2.295 |
03:27 ET | 6051 | 2.295 |
03:30 ET | 10302 | 2.3 |
03:32 ET | 30517 | 2.295 |
03:34 ET | 103042 | 2.28 |
03:36 ET | 13994 | 2.275 |
03:38 ET | 10282 | 2.285 |
03:39 ET | 5497 | 2.285 |
03:41 ET | 23575 | 2.295 |
03:43 ET | 4580 | 2.295 |
03:45 ET | 1964 | 2.3 |
03:48 ET | 1500 | 2.295 |
03:50 ET | 6685 | 2.295 |
03:52 ET | 3871 | 2.295 |
03:54 ET | 12402 | 2.3 |
03:56 ET | 15589 | 2.295 |
03:57 ET | 20162 | 2.3 |
03:59 ET | 138828 | 2.3 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Taysha Gene Therapies Inc | 457.1M | -1.9x | --- |
AC Immune SA | 387.9M | -5.6x | --- |
Uniqure NV | 416.1M | -1.3x | --- |
C4 Therapeutics Inc | 443.1M | -2.7x | --- |
Q32 Bio Inc | 458.0M | -1.4x | --- |
Ocugen Inc | 419.5M | -7.0x | --- |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.1M |
---|---|
Revenue (TTM) | $14.2M |
Shares Outstanding | 201.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $-1.19 |
Book Value | $0.40 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 32.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -576.49% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.